MCM3 and benign prostatic hyperplasia: To assess the significance of our ARCaP EMT model for clinical prostate cancer progression, we evaluated the expression of MCM3 in normal prostate (n = 12), benign prostatic hyperplasia (BPH, n = 6), and primary prostate carcinoma tissues (n = 12).